Why the study?
Comorbid depression in T2DM increases the risk of cardiovascular events and death, while bidirectional relationships and pharmacological interactions between both conditions affect cardiovascular outcomes.
This review highlights the bidirectional relationship between T2DM and depression, emphasizing that their comorbidity and combined pharmacological treatments may exacerbate cardiovascular disease risk.
Comorbid T2DM and depression may elevate CV risk; leaves open whether antidepressant-hypoglycemic combinations increase first MI incidence.
Depression is a common comorbidity of type 2 diabetes mellitus (T2DM). T2DM with comorbid depression increases the risk of cardiovascular events and death. Depression and T2DM and its macrovascular complications exhibited a two-way relationship. Regarding treatment, antidepressants can affect the development of T2DM and cardiovascular events, and hypoglycemic drugs can also affect the development of depression and cardiovascular events. The combination of these two types of medications may increase the risk of the first myocardial infarction. Herein, we review the latest research progress in the exacerbation of cardiovascular disease due to T2DM with comorbid depression and provide a rationale and an outlook for the prevention and treatment of cardiovascular disease in T2DM with comorbid depression.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2022) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: